IOncology

The 14th Shanghai Urologic Oncology Academic Conference and the Annual Meeting of the Chinese Anti-Cancer Association Male Reproductive System Tumor Committee (CACA-GO) took place from December 6–8,2024 in Shanghai. The conference invited several internationally renowned experts in urologic oncology for academic lectures and surgical demonstrations.Dr. Stephen Freedland from Cedars-Sinai Medical Center in the United States delivered two impactful presentations titled “EMBARK and Something Related to BCR” and “Race and Prostate Cancer – Access to Care vs. Biology or Both?” In an interview with Urology Frontier, Dr. Freedland further discussed the latest progress in the treatment of biochemical recurrence (BCR) in prostate cancer and topics related to racial disparities in healthcare.

The 47th San Antonio Breast Cancer Symposium (SABCS) successfully took place in San Antonio, USA. As one of the largest and most prestigious scientific gatherings in breast cancer research, SABCS showcased the latest findings, clinical practices, treatment advances, and technological innovations over the past year. Among the presented studies, an oral presentation (GS3-05) analyzed the efficacy of neoadjuvant chemotherapy combined with atezolizumab, followed by adjuvant atezolizumab in triple-negative breast cancer (TNBC) patients. Oncology Frontier invited Dr. Ting Luo from the West China Hospital of Sichuan University to introduce this study and provide expert commentary.

At the 2024 San Antonio Breast Cancer Symposium (SABCS), a study led by Professor Noor Wortelboer from Erasmus University Medical Center in Rotterdam was presented during the "Poster Spotlight 2: Personalizing CDK 4/6 Inhibitor Therapy for Patients with Metastatic Breast Cancer: Survival, QOL, and Biomarkers" session. This research, based on the SONIA trial data, provided an in-depth analysis of health-related quality of life (HRQoL) outcomes in patients using CDK4/6 inhibitors (CDK4/6i) at different treatment lines. The findings offer crucial insights into how CDK4/6i impacts patients’ quality of life and serve as valuable guidance for optimizing treatment strategies in advanced breast cancer. Oncology Frontier invited Dr. Yan Xue from Xi’an International Medical Center Oncology Hospital to interpret and comment on the study's data.

The 47th San Antonio Breast Cancer Symposium (SABCS) recently concluded successfully in San Antonio, USA. SABCS is the world’s largest conference in the field of breast cancer, attracting more than 10,000 registered participants from 102 countries. Over four days, the conference featured thousands of keynote speeches and research abstracts. On December 11, during the second day of the conference, Nobel Laureate in Physiology or Medicine (2019) Professor William Kaelin delivered a highly acclaimed keynote address on the topic of "Tumor Genetics and Targeted Drug Development." Oncology Frontier had the privilege of interviewing Dr. Guojun Zhang from Yunnan Cancer Hospital for a comprehensive review and summary of this lecture.

The "2024 Cross-Strait Breast Cancer Forum," held alongside the 2024 Academic Annual Meeting of the Breast Disease Branch of the Fujian Medical Association, the 2024 Annual Meeting of the Oncology Physicians Branch of the Fujian Medical Doctor Association, and the Fujian Breast Cancer Prevention and Treatment Workshop, took place from December 13 to 15, 2024, in Fuzhou. The forum brought together renowned experts to discuss the latest advancements in breast cancer and oncology. Oncology Frontier interviewed the forum chair, Dr. Jian Liu from Fujian Cancer Hospital, who shared insights into the event's agenda and its key highlights.

At the recent San Antonio Breast Cancer Symposium (SABCS), Dr. Jiong Wu from Fudan University Shanghai Cancer Center and his team presented several significant research findings, offering new insights into breast cancer treatment.

The 47th San Antonio Breast Cancer Symposium (SABCS) was grandly held from December 10–13, 2024, in San Antonio, USA, showcasing significant global advancements in breast cancer research. During the conference, Dr. Xiaojia Wang from the Cancer Hospital of the University of the Chinese Academy of Sciences (Zhejiang Cancer Hospital) presented several important research findings. These included innovative treatment strategies with the new PD-1/VEGF bispecific antibody Ivosidenib and the novel antibody-drug conjugate (ADC) ARX788. Additionally, multiple real-world studies (RWS) provided valuable clinical insights into intensified adjuvant therapy for early-stage HER2-positive breast cancer, systemic therapy for advanced breast cancer, and breast cancer bone metastases. These contributions amplified the voice of China in breast cancer research at SABCS.Oncology Frontier interviewed Dr. Xiaojia Wang at the conference to share key data from these studies.

The de-escalation strategy for axillary management in breast cancer has been a consistent research focus in breast surgery. Last year, the SOUND study explored whether certain low-risk patients undergoing breast-conserving surgery could avoid sentinel lymph node biopsy (SLNB). At the 2024 San Antonio Breast Cancer Symposium (SABCS), the INSEMA study, a similar investigation, was presented. Oncology Frontier invited Dr. Yiding Chen from The Second Affiliated Hospital of Zhejiang University School of Medicine to provide an in-depth analysis of the INSEMA study.

The "2024 Yixian Breast Cancer Conference and the Second China Young Breast Cancer Consensus Conference" took place in Guangzhou from December 27 to 28, 2024. The conference explored cutting-edge topics such as the evolving epidemiology of young breast cancer, screening strategies, the impact of genetic mutations, treatment, and recovery approaches. Highlights included the release of the YBCC Consensus on Diagnosis and Treatment (Patient Edition), the China Genetic Mutation Pathogenicity Database, and the Young Breast Cancer Quality of Life Scale. Oncology Frontier interviewed Dr. Qiang Liu, the conference chair from Sun Yat-sen Memorial Hospital, Sun Yat-sen University, to discuss key highlights, the unique epidemiological characteristics of young breast cancer, and future plans for advancing standardized care in this area.

On December 28, 2024, the year-end meeting of the Youth Expert Committee of the Chinese Society of Clinical Oncology (CSCO) was successfully held in Shanghai. This event brought together renowned experts and promising young talents from across the country to explore new directions in cancer treatment. Oncology Frontier had the honor of interviewing Dr. Biyun Wang, Chair of the conference and a leading expert at Fudan University Shanghai Cancer Center, who shared key highlights of the conference, insights on the development of young oncologists, the achievements of CSCO YOUNG, and future plans.